CRIS Current Research Information System

MARZOCCHI, GIULIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.710
AS - Asia 3.574
EU - Europa 2.307
AF - Africa 211
SA - Sud America 167
Continente sconosciuto - Info sul continente non disponibili 138
OC - Oceania 7
Totale 10.114
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.619
VN - Vietnam 1.386
CN - Cina 801
SG - Singapore 757
IT - Italia 512
GB - Regno Unito 470
SE - Svezia 327
DE - Germania 270
HK - Hong Kong 187
FR - Francia 142
IN - India 134
NL - Olanda 123
BR - Brasile 117
RU - Federazione Russa 103
KR - Corea 79
IE - Irlanda 74
UA - Ucraina 63
CI - Costa d'Avorio 57
CA - Canada 51
FI - Finlandia 50
ZA - Sudafrica 47
JP - Giappone 39
SC - Seychelles 39
BD - Bangladesh 38
TG - Togo 38
EE - Estonia 33
BG - Bulgaria 31
CH - Svizzera 31
JO - Giordania 28
PH - Filippine 25
AR - Argentina 23
TH - Thailandia 21
BE - Belgio 18
MX - Messico 18
NG - Nigeria 13
AT - Austria 11
CL - Cile 11
TR - Turchia 11
TW - Taiwan 11
ES - Italia 10
IR - Iran 10
ID - Indonesia 9
PL - Polonia 9
SA - Arabia Saudita 9
GR - Grecia 7
CZ - Repubblica Ceca 6
EC - Ecuador 6
AU - Australia 5
IQ - Iraq 5
MY - Malesia 5
CR - Costa Rica 4
GT - Guatemala 4
HN - Honduras 4
IL - Israele 4
KE - Kenya 4
PK - Pakistan 4
DZ - Algeria 3
MA - Marocco 3
PY - Paraguay 3
AE - Emirati Arabi Uniti 2
BO - Bolivia 2
CO - Colombia 2
JM - Giamaica 2
LT - Lituania 2
NI - Nicaragua 2
NO - Norvegia 2
PT - Portogallo 2
RO - Romania 2
RS - Serbia 2
TN - Tunisia 2
VE - Venezuela 2
AL - Albania 1
AO - Angola 1
BS - Bahamas 1
BY - Bielorussia 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GM - Gambi 1
GP - Guadalupe 1
HU - Ungheria 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LU - Lussemburgo 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
NC - Nuova Caledonia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
SI - Slovenia 1
SN - Senegal 1
SV - El Salvador 1
SX - ???statistics.table.value.countryCode.SX??? 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 9.975
Salva come PNG Salva come JPEG
Città #
Singapore 542
Ashburn 403
Southend 394
Chandler 312
Ho Chi Minh City 307
Fairfield 274
Hanoi 238
Dong Ket 207
San Jose 206
Hong Kong 181
Hefei 167
Woodbridge 153
Seattle 138
Wilmington 128
Houston 126
Ann Arbor 116
Cambridge 116
Bologna 113
Beijing 111
Princeton 91
Dallas 87
New York 81
Santa Clara 75
Seoul 75
Dublin 74
Boardman 69
Council Bluffs 66
Abidjan 57
Lauterbourg 49
Helsinki 44
Los Angeles 42
Turin 41
Lomé 38
Nanjing 37
Westminster 36
Milan 35
Padova 34
Bremen 33
Haiphong 33
Chicago 32
Jacksonville 32
Sofia 31
Tokyo 30
Berlin 28
Amman 27
Florence 27
Jinan 26
Da Nang 25
Frankfurt am Main 24
Munich 24
Bern 22
Hyderabad 22
Phoenix 20
São Paulo 20
Buffalo 19
Redondo Beach 19
Saint Petersburg 19
Shenyang 19
Biên Hòa 18
Brussels 18
San Diego 18
Guangzhou 17
Bengaluru 16
Redmond 16
Nanchang 15
Can Tho 14
Ha Long 14
Tianjin 14
Atlanta 13
Thái Nguyên 13
Toronto 13
Abeokuta 12
Hebei 12
Orem 12
Quận Bình Thạnh 12
Redwood City 12
Zhengzhou 12
Brooklyn 11
Nuremberg 11
San Francisco 11
Amsterdam 10
Castelfranco Emilia 10
Fabriano 10
Falkenstein 10
Falls Church 10
Hangzhou 10
London 10
Paris 10
Shanghai 10
Quận Một 9
Casalecchio di Reno 8
Chengdu 8
Des Moines 8
Düsseldorf 8
Johannesburg 8
Taizhou 8
Bắc Ninh 7
Changsha 7
Charlotte 7
Denver 7
Totale 6.274
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 731
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 371
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 359
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 276
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 262
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 260
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 244
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. 238
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS 232
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 232
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 223
Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients 222
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 221
Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities 220
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 217
t(5;12)(q31;p13)/ETV6::ACSL6 and t(6;9)(p23;q34)/DEK::NUP214 concurrence in acute myeloid leukemia: an unusual association of two rare abnormalities 217
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 209
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma 208
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP. 205
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 197
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis 194
Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma 193
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. 192
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 191
Acute promyelocytic leukemia with amplification of PML-RARalpha rearrangement:clinical implications 189
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 188
Molecular and cytogenetic characterization of a new case of t(5;17)(q35;q21) variant acute promyelocytic leukemia 185
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. 177
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 175
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis 172
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features 170
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation 169
GENOME-WIDE SCREENING OF CHRONIC MYELOID LEUKEMIA PATIENTS BY SNP ARRAYS: ALTERATIONS ASSOCIATED WITH DISEASE PROGRESSION 169
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib 168
Increased donor CD86+CD14+ cells in the bone marrow and peripheral blood of patients with chronic graft-versus-host disease. 165
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 163
FGFR1 and KAT6A rearrangements in patients with hematological malignancies and chromosome 8p11 abnormalities: biological and clinical features 163
Mobilization of bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver transplantation and liver resection. 162
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy 159
Emergence and Cytogenetic Clonal Evolution of Chromosome 7 Abnormalities in Myeloid Malignancies: Investigating the Role of Telomere Dysfunction 157
Rare, but complex chromosomal rearrangements, defined "Chromoanagenesis”, caused by single-step or stepwise catastrophic genomic events, significantly impact on Multiple Myeloma patients 149
Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4 141
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain 133
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up 117
null 104
Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies 103
null 102
Proteasome inhibitors: Bortezomib in multiple myeloma 101
Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma 99
null 98
The road to cure in multiple myeloma: Incorporation of novel agents into autologous stem cell transplantation 71
Erratum: Additional chromosomal abnormalities in Philadelphia-positive clone: Adverse prognostic influence on frontline imatinib therapy: A GIMEMA Working Party on CML analysis (Blood (2012) 120:4 (761-767)) 51
Totale 10.114
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.398
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.398
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022808 0 0 0 107 79 43 23 61 41 121 167 166
2022/20231.215 120 193 66 170 67 97 39 69 195 38 115 46
2023/2024394 24 42 23 40 39 106 16 35 6 18 28 17
2024/20251.197 65 108 91 101 150 54 106 43 16 176 76 211
2025/20263.398 325 755 281 223 310 148 260 92 578 228 96 102
2026/2027547 54 117 199 177 0 0 0 0 0 0 0 0
Totale 10.114